Yan C - Search Results

1

Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia.

Tang J, Tu S, Lin G, Guo H, Yan C, Liu Q, Huang L, Tang N, Xiao Y, Pope RM, Rajaram MVS, Amer AO, Ahmer BM, Gunn JS, Wozniak DJ, Tao L, Coppola V, Zhang L, Langdon WY, Torrelles JB, Lipkowitz S, Zhang J. Tang J, et al. Among authors: yan c. J Exp Med. 2020 Apr 6;217(4):e20182091. doi: 10.1084/jem.20182091. J Exp Med. 2020. PMID: 31999304 Free PMC article.

2

HECT E3 Ubiquitin Ligase Nedd4 Is Required for Antifungal Innate Immunity.

Nuro-Gyina PK, Tang N, Guo H, Yan C, Zeng Q, Waldschmidt TJ, Zhang J. Nuro-Gyina PK, et al. Among authors: yan c. J Immunol. 2021 Aug 1;207(3):868-877. doi: 10.4049/jimmunol.2100083. Epub 2021 Jul 19. J Immunol. 2021. PMID: 34282001 Free PMC article.

3

Cbl-b restrains priming of pathogenic Th17 cells via the inhibition of IL-6 production by macrophages.

Zeng Q, Tang N, Ma Y, Guo H, Zhao Y, Tang R, Yan C, Ouyang S, Langdon WY, Yang H, O'Brien MC, Zhang J. Zeng Q, et al. Among authors: yan c. iScience. 2022 Sep 15;25(10):105151. doi: 10.1016/j.isci.2022.105151. eCollection 2022 Oct 21. iScience. 2022. PMID: 36185364 Free PMC article.

4

SNPs affecting the clinical outcomes of regularly used immunosuppressants.

Meng HY, Luo ZH, Hu B, Jin WL, Yan CK, Li ZB, Xue YY, Liu Y, Luo YE, Xu LQ, Yang H. Meng HY, et al. Pharmacogenomics. 2018 Apr;19(5):495-511. doi: 10.2217/pgs-2017-0182. Epub 2018 Mar 8. Pharmacogenomics. 2018. PMID: 29517418 Review.

5

The Application of Machine Learning Techniques in Clinical Drug Therapy.

Meng HY, Jin WL, Yan CK, Yang H. Meng HY, et al. Curr Comput Aided Drug Des. 2019;15(2):111-119. doi: 10.2174/1573409914666180525124608. Curr Comput Aided Drug Des. 2019. PMID: 29804538 Review.

6

Factors affecting minimal manifestation status induction in myasthenia gravis.

Li Y, Yang S, Dong X, Li Z, Peng Y, Jin W, Chen D, Zhou R, Jiang F, Yan C, Yang H. Li Y, et al. Among authors: yan c. Ther Adv Neurol Disord. 2022 Mar 29;15:17562864221080520. doi: 10.1177/17562864221080520. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35371293 Free PMC article.

7

Evaluation of outcome measures for myasthenia gravis subgroups.

Luo Y, Dong X, Peng Y, Cui B, Yan C, Jin W, Li Y, Zhou R, Huang K, Yang H. Luo Y, et al. Among authors: yan c. J Clin Neurosci. 2021 Sep;91:270-275. doi: 10.1016/j.jocn.2021.07.020. Epub 2021 Jul 27. J Clin Neurosci. 2021. PMID: 34373039

8

Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis.

Jin W, Yang Q, Peng Y, Yan C, Li Y, Luo Z, Xiao B, Xu L, Yang H. Jin W, et al. Among authors: yan c. Cell Discov. 2021 Sep 14;7(1):85. doi: 10.1038/s41421-021-00314-w. Cell Discov. 2021. PMID: 34521820 Free PMC article.

9

Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.

Meng HY, Li X, Jin WL, Yan CK, Dong XH, Xu Q, Peng YY, Li ZB, Li Y, Luo ZH, Xu LQ, Yang H. Meng HY, et al. Eur J Clin Pharmacol. 2020 May;76(5):659-671. doi: 10.1007/s00228-019-02803-0. Epub 2020 Jan 18. Eur J Clin Pharmacol. 2020. PMID: 31955224

10

Erythrocytes: Member of the immune system that should not be ignored.

Ren Y, Yan C, Yang H. Ren Y, et al. Among authors: yan c. Crit Rev Oncol Hematol. 2023 Jul;187:104039. doi: 10.1016/j.critrevonc.2023.104039. Epub 2023 May 24. Crit Rev Oncol Hematol. 2023. PMID: 37236411 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,899 results

Search Page